Austrian National Cancer Registry

Vienna, Austria

Austrian National Cancer Registry

Vienna, Austria
SEARCH FILTERS
Time filter
Source Type

Brenner H.,German Cancer Research Center | Bouvier A.M.,Registre Bourguignon des Cancers Digestifs | Foschi R.,Instituto Nazionale Tumori | Hackl M.,Austrian National Cancer Registry | And 3 more authors.
International Journal of Cancer | Year: 2012

Colorectal cancer (CRC) is the second most common cause of death due to cancer causing death in Europe, accounting for more than 200,000 deaths per year. Prognosis strongly depends on stage at diagnosis, and the disease can be cured in most cases if diagnosed at an early stage. We aimed to assess trends and recent developments in 5-year relative survival in European countries, with a special focus on age, stage at diagnosis and anatomical cancer subsite. Data from 25 population-based cancer registries from 16 European countries collected in the context of the EUROCARE-4 project were analyzed. Using period analysis, age-adjusted and age-specific 5-year relative survival was calculated by country, European region, stage and cancer subsite for time periods from 1988-1990 to 2000-2002. Survival substantially increased over time in all European regions. In general, increases were more pronounced in younger than in older patients, for earlier than for more advanced cancer stages and for rectum than for colon cancer. Substantial variation of CRC survival between European countries and between age groups persisted and even tentatively increased over time. There is a huge potential for reducing the burden of CRC in Europe by more widespread and equal delivery of existing options of effective early detection and curative treatment to the European population. Copyright © 2011 UICC.


PubMed | Austrian National Cancer Registry, Saarland Cancer Registry, Malta National Cancer Registry, National Institute for Health Development and 4 more.
Type: | Journal: European journal of cancer (Oxford, England : 1990) | Year: 2015

Previous population-based studies revealed major variation in survival for patients with colorectal cancer (CRC) in Europe by age and between different countries and regions, but also a sustained improvement in survival for patients with CRC in recent years. This EUROCARE-5 paper aims to update available knowledge from previous studies and to provide the latest survival estimates for CRC patients from Europe.The study analysed data of patients diagnosed with CRC from population-based cancer registries diagnosed in 29 European countries. Estimates of 1-year and 5-year relative survival (RS) were derived for patients diagnosed in 2000-2007 by European region, country and age at diagnosis. Additionally to these cohort estimates, time trends in 5-year RS were obtained for the calendar periods 1999-2001 and 2005-2007, using the period analysis methodology.European average 5-year RS for patients diagnosed with colon and rectum cancer was 57% and 56%, respectively. The analyses showed persistent differences in cancer survival across Europe with lowest survival for CRC patients observed in Eastern Europe. The analyses further showed a strong gradient in age-specific survival. Even though the study revealed sustained improvement in patient survival between 1999-2001 and 2005-2007 (absolute increase of 4 and 6 percentage points for colon and rectum, respectively), the differences in the survival for CRC patients observed at the beginning of the millennium persisted over time.Although survival for CRC patients in Europe improved markedly in the study period, significant geographic variations and a strong age gradient still persisted. Enhanced access to effective diagnostic procedures and treatment options might be the keys to reducing the existing disparities in the survival of CRC patients across Europe.


PubMed | Brigham and Women's Hospital, University of California at San Francisco, Institute for Clinical Epidemiology, Austrian National Cancer Registry and Medical University of Vienna
Type: | Journal: European journal of cancer (Oxford, England : 1990) | Year: 2016

Incidence rates of melanoma, generated by cancer registries (CRs), are susceptible to reporting inconsistencies due to increasing decentralisation of diagnosis. We therefore independently assessed the burden of melanoma in Austria.We collected histopathological reports on melanoma of all patients diagnosed in Austria in 2011. Demographic and clinical characteristics, histopathological tumour stages were assessed. Their regional distributions and incidence rates were analysed and compared with data of national and international CRs.A total of 5246 patients were diagnosed with 1951 in-situ and 3295 invasive melanomas in Austria in 2011 (population 8.4 million). Age, sex and anatomic distribution corresponded to findings in other European countries, however, the incidence of 25/100,000 (world age-standardised rate) for invasive melanomas was two-fold higher than published by the Austrian CR (12/100,000). Varying frequencies in diagnosing thin melanomas (1mm; n=4415) accounted exclusively for significant regional disparities, while advanced tumours (>1mm; n=761) were evenly distributed. Western Austria showed the highest rates (36/100,000). Patients from eastern Austria whose melanomas were diagnosed in laboratories in western Austria (n=76) showed significantly higher proportions of in-situ lesions (n=43; 57%) compared to those whose tumours were diagnosed in eastern Austria (n=4014; in-situ=1369; 34%) (p<0.0001).In Austria, the melanoma burden and its potential socio-economic implications are significantly underestimated. Similarities of incidences indicate this could affect other European countries with well-established CRs and compromise international comparability of data. Austrian regional disparities suggest overdiagnosis of thin melanomas due to the variability of pathologists thresholds for the diagnosis of early stage tumours.


Capper D.,University of Heidelberg | Capper D.,German Cancer Research Center | Berghoff A.S.,Medical University of Vienna | Magerle M.,Medical University of Vienna | And 15 more authors.
Acta Neuropathologica | Year: 2012

Brain metastases (BM) are frequent and carry a dismal prognosis. BRAF V600E mutations are found in a broad range of tumor types and specific inhibitors targeting BRAF V600E protein exist. We analyzed tumoral BRAF V600E-mutant protein expression using the novel mutation-specific antibody VE1 in a series of 1,120 tumor specimens (885 BM, 157 primary tumors, 78 extra-cranial metastases) of 874 BM patients. In 85 cases, we performed validation of immunohistochemical results by BRAF exon 15 gene sequencing. BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas. BRAF V600E expression showed high intra-tumoral homogeneity and was similar in different tumor manifestations of individual patients. VE1 immunohistochemistry and BRAF exon 15 sequencing were congruent in 68/70 (97.1%) cases, but VE1 immunostaining identified small BRAF V600E expressing tumor cell aggregates in 10 cases with inconclusive genetic results. Melanoma patients with BRAF V600E mutant protein expressing tumors were significantly younger at diagnosis of the primary tumor and at operation of BM than patients with non-mutated tumors. In conclusion, expression of BRAF V600E mutant protein occurs in approximately 6% of BM and is consistent in different tumor manifestations of the same patient. Thus, BRAF V600E inhibiting therapies seem feasible in selected BM patients. Immunohistochemical visualization of V600E-mutant BRAF protein is a promising tool for patient stratification. An integrated approach combining both, VE1 immunohistochemistry and genetic analysis may increase the diagnostic accuracy of BRAF mutation analysis. © 2011 Springer-Verlag.


Preusser M.,Medical University of Vienna | Streubel B.,Medical University of Vienna | Berghoff A.S.,Medical University of Vienna | Hainfellner J.A.,Medical University of Vienna | And 10 more authors.
Histopathology | Year: 2014

Background: CMET represents an emerging therapy target for monoclonal antibodies and tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). Methods: We investigated CMET gene amplification status by fluorescence in-situ hybridization (FISH) and CMET protein expression by immunohistochemistry in a large series of 209 NSCLC brain metastases (BM; 165 adenocarcinoma, 20 squamous cell carcinoma, 11 adenosquamous carcinomas, 11 large cell carcinomas and two large cell neuroendocrine carcinomas) and correlated our results to clinic-pathological parameters and molecular data from previous studies. Results: We found CMET gene amplification in 36/167 (21.6%) and CMET protein expression in 87/196 (44.4%) of evaluable BM. There was a strong correlation between the presence of CMET gene amplification and CMET protein expression (P < 0.001, chi-square test). Furthermore, presence of CMET amplification correlated positively with presence of ALK amplifications (P = 0.039, chi-square test) and high HIF1 alpha index (P = 0.013, Mann-Whitney U-test). Neither CMET expression nor CMET gene amplification status correlated with patient outcome parameters or known prognostic factors. Conclusions: CMET overexpression and CMET amplification are commonly found in NSCLC BM and may represent a promising therapeutic target. © 2014 John Wiley & Sons Ltd.


Woehrer A.,Medical University of Vienna | Slavc I.,Medical University of Vienna | Waldhoer T.,Medical University of Vienna | Heinzl H.,Medical University of Vienna | And 5 more authors.
Cancer | Year: 2010

Background: Atypical teratoid/rhabdoid tumors are highly malignant embryonal central nervous system (CNS) tumors that were defined as an entity in 1996. As compared with other malignant CNS tumors, their biological behavior is particularly aggressive, but patients may benefit from an intensified treatment. Atypical teratoid/rhabdoid tumors display a complex histomorphology, which renders them prone to misdiagnosis. They occur predominantly in young children, with an estimated prevalence of 1% to 2% among all pediatric CNS tumors. However, population-based data on the incidence of these tumors are not yet available. Methods: A nation-wide survey of malignant high-grade CNS tumors (World Health Organization grade III/IV), diagnosed in children (aged birth to 14 years) from 1996 to 2006 was conducted by the Austrian Brain Tumor Registry. A central histopathology review was performed including the assessment of SMARCB1 (INI1) protein status. Results: A total of 311 newly diagnosed, malignant CNS tumors were included. Atypical teratoid/rhabdoid tumors constituted the sixth most common entity (6.1%), referring to an age-standardized incidence rate of 1.38 per 1,000,000 person-years in children. Peak incidence was found in the birth to 2 years age group, where they were as common as CNS primitive neuroectodermal tumors and medulloblastomas. A total of 47.4% of atypical teratoid/rhabdoid tumors were initially diagnosed, whereas 52.6% were retrospectively detected by the central review. The 5-year survival of atypical teratoid/rhabdoid tumor patients was 39.5%, with 66.7% in the correctly diagnosed group versus 15.0% in the not recognized group (P =.0469). Conclusions: Clinicians and pathologists should be aware of the high incidence of atypical teratoid/rhabdoid tumors in young children to optimize diagnostic and therapeutic management of patients with these tumors. Copyright © 2010 American Cancer Society.


PubMed | Medical University of Vienna, Austrian National Cancer Registry and Kaiser Franz Josef Spital
Type: | Journal: Wiener klinische Wochenschrift | Year: 2016

The aim of this study was to analyze the impact of gender on tumor stage, overall and cancer-specific mortality of upper urinary tract urothelial cancer (UTUC) in a population-based, nationwide analysis.All Austrian patients with UTUC diagnosed between 1983 and 2010 were included in this study. Overall mortality was estimated by the Kaplan-Meier method. Cancer-specific (UTUC) mortality was estimated by cumulative incidence with mortality due to other causes as a competing risk. The effect of age was adjusted in a descriptive as well as a statistical inferential way.This study included 2066 patients (men n= 1169, mean age 68.311.5 years, women n= 897, 72.610.4 years). Tumor stage distribution was as follows: pT1: men n= 411, women n= 268, pT2: men n= 263, women n= 187, pT3: men n= 382, women n= 328 and pT4: men n= 113, women n= 114. The male:female ratio continuously declined from 1.5 for pT1 tumors to 1.4 for pT2 tumors, 1.2 for pT3 tumors and 1.0 for pT4-tumors. In the entire cohort the 5year cumulative overall mortality was 57% for women versus 50% for men (p= 0.0002). For pT1 (women 33%, men 31%) and pT2 stage tumors (women 45%, men 45%) the 5year overall mortality was comparable between both sexes. In pT3 (women 68%, men 62%) and pT4 (women 95%, men 87%) tumors women had a higher overall mortality rate. The 5year cancer-specific mortality (CSM) of the entire cohort was 12% for women and 10% for men (p= 0.067): pT1 women 5% men 3%, pT2 women 9% men 10%, pT3 women 14% men 11% and pT4 women 29% men 27%.In this population-based nationwide analysis, sex differences were notable for UTUC. Women tended to have more advanced tumor stages at diagnosis and a higher overall and cancer-specific mortality in advanced tumor stages.


Hackl M.,Austrian National Cancer Registry | Waldhoer T.,Medical University of Vienna
European Journal of Public Health | Year: 2013

Background: The international comparability of data from population-based cancer registries depends strongly on the completeness of case ascertainment. Furthermore, Austrian observed incidence rates suggest that the completeness of case ascertainment differs between Austrian federal states. Completeness of case ascertainment is to be investigated on national and regional level. Methods: We used the flow method to evaluate the completeness of the Austrian National Cancer Registry. This method is based on the logical flow of data in the registration system, and on the time distribution of various probabilities inherent in this flow. Results: Overall completeness of the Austrian cancer incidence data 2005 was 94.2% after a registration period of 5 years. The flow method found striking differences in completeness between the federal states, which are contrary to the time series analyses. Conclusion: Overall completeness of the Austrian National Cancer Registry is in concordance with estimates from international registries. The biggest part of the decrease of incidence rates in the past 2 published years seems to be a result of incompleteness. The importance of the registration date of a cancer case and the survival time on completeness estimation using the flow method has become apparent. Further investigation into the comparability of registration date between the federal states and into the quality of survival time estimates is recommended. © 2012 The Author 2012. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.


Berghoff A.S.,Medical University of Vienna | Ilhan-Mutlu A.,Medical University of Vienna | Wohrer A.,Medical University of Vienna | Hackl M.,Austrian National Cancer Registry | And 8 more authors.
Strahlentherapie und Onkologie | Year: 2014

Background. Survival upon diagnosis of brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) is highly variable and established prognostic scores do not include tissue-based parameters. Methods. Patients who underwent neurosurgical resection as first-line therapy for newly diagnosed NSCLC BM were included. Microvascular density (MVD), Ki67 tumor cell proliferation index and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry. Results. NSCLC BM specimens from 230 patients (151 male, 79 female; median age 56 years; 199 nonsquamous histology) and 53/230 (23.0%) matched primary tumor samples were available. Adjuvant whole-brain radiation therapy (WBRT) was given to 153/230 (66.5%) patients after neurosurgical resection. MVD and HIF-1 alpha indices were significantly higher in BM than in matched primary tumors. In patients treated with adjuvant WBRT, low BM HIF-1 alpha expression was associated with favorable overall survival (OS), while among patients not treated with adjuvant WBRT, BM HIF-1 alpha expression did not correlate with OS. Low diagnosis-specific graded prognostic assessment score (DS-GPA), low Ki67 index, high MVD, low HIF-1 alpha index and administration of adjuvant WBRT were independently associated with favorable OS. Incorporation of tissue-based parameters into the commonly used DS-GPA allowed refined discrimination of prognostic subgroups. Conclusion. Ki67 index, MVD and HIF-1 alpha index have promising prognostic value in BM and should be validated in further studies. © 2014 Springer-Verlag.


Pinter M.,Medical University of Vienna | Hucke F.,Medical University of Vienna | Zielonke N.,Austrian National Cancer Registry | Waldhor T.,Medical University of Vienna | And 3 more authors.
Liver International | Year: 2014

Background & Aims: The epidemiology of biliary tract cancers (BTC) varies between geographical regions and has changed over time globally. We investigated the incidence and mortality trends of patients diagnosed with BTC over a 20-year period in Austria. Methods: Patients diagnosed with intrahepatic (iCCC)/extrahepatic cholangiocarcinoma (eCCC), ampullary carcinoma, gall bladder carcinoma (GBC), overlapping lesions or unspecified carcinomas of the biliary tract and liver were included. Data on age-adjusted incidence were obtained from the Austrian National Cancer Registry which compiles data on all newly diagnosed cancers. Data on age-adjusted mortality were obtained from the national death registry (Statistics Austria). Results: Between 1990 and 2009, 15201 patients were diagnosed with BTC (m/f=42/58%; mean age, 73 years). The median survival of all patients with BTC was 4.8 months with a 1-/5-year survival rate of 31%/10%. In iCCC, the incidence and mortality rates increased from 1990 to 2009 in both men and women while in eCCC, the incidence and mortality rates decreased over time in both sexes. In ampullary carcinoma, the incidence slightly decreased in men and remained stable in women. The mortality rate remained stable in both sexes. In GBC, the age-adjusted incidence and mortality rates dramatically decreased in both sexes. Conclusions: GBC and iCCC were the most common entities amongst BTC. While incidence and mortality rates of iCCC increased in men and women over time, incidence and mortality rates of eCCC and GBC decreased in both sexes. Other carcinomas of the biliary tract i.e. ampullary carcinoma were rarely diagnosed. © 2013 John Wiley & Sons A/S.

Loading Austrian National Cancer Registry collaborators
Loading Austrian National Cancer Registry collaborators